Table 3 Patient characteristics
Study | Recruitment period | Intervention | Cases | M/F | Median/mean age (range) | Pathology (adeno/SCC/other) | TNM stage | Tumor site (U/M/L/GEJ) | ASA grade | Mean/median follow up (months) | Neoadjuvant treatment (no/CT/CRT) |
|---|---|---|---|---|---|---|---|---|---|---|---|
Barbour et al. [17] | 1988–2011 | TAMK | 377 | 316/61 | 64 (27–84) | 299/78/0 | 51/80/125/121/0(0/I/II/III/IV) | 0/42/299/36 | 275/102 (1&2/3&4) | 27 | 175/87/115 |
Wang et al. [19] | 2004–2013 | MIE †| 444 | 362/82 | 56 (32–77) | 0/444/0 | 62/254/100/28 (0&I/II/III/IV) | 63/244/137/0 | 321/107/16 (1/2/3) | 27 | 364/22/58 |
Maas et al. [20] | 2009–2011 | MIE †| 59 | 43/16 | 62 (34–75) | 35/24/0 | 1/4/26/11/4/9/4 (0/I/II/III/IV/No residual tumor of LN. matas./no surgery) | N/A | 10/34/14/1 (1/2/3/4) | 12 | 0/5/54 |
Wang et al. [15] | 2007–2008 | MIE ‡ | 27 | 19/8 | 60.7 ± 9.3 | 1/25/1 | 6/14/4/3/0 (0&I/IIa/IIb/III/IV) | 4/17/6//0 | N/A | 6 | 27/0/0 |
Parameswaran et al. [16] | 2005–2007 | MIE ‡ | 62 | 56/6 | 67 (49–80) | 55/5/2 | 3/7/21/27/4 (0/I/II/III/IV) | N/A | N/A | 12 | 0/48/0 |
Nafteux et al. [18] | 2005–2010 | MIE ‡ | 65 | 52/13 | 63.1(41–82) | 52/N/A/13 | 10/55/0/0/0 (0/I/II/III/IV) | N/A | N/A | 72 | 65/0/0 |